характеристики взаимодействия miRNA c 5'UTR, CDS и 3'UTR mRNA кандидатных генов метаболического синдром
DOI:
https://doi.org/10.26577/eb-2019-1-1385Аннотация
Изучение генетической природы метаболического синдрома является одной из наиболее перспективных областей молекулярной медицины во всем мире. Выявление генетических маркеров позволяет разработать раннюю диагностику заболевания и оптимизировать профилактику метаболического синдрома. Обнаружение биомаркеров должно улучшить терапию и оценку риска сердечно-сосудистых заболеваний. Поиск эффективных маркеров метаболического синдрома является предметом текущих исследований. Взаимодействие miRNA с mRNA кандидатных генов было предсказано с помощью программы MirTarget. Гены, ответственные за развитие метаболического синдрома, регулируемые микроРНК, были отобраны путем поиска в базе PubMed. Гены ADRA2A и SCAP регулируются 12 и 15 miRNAs в 5'UTR, наибольшая энергия связывания составляет -144 кДж/моль и -151 кДж/моль соответственно. В CDS mRNA генов AR, CEBPA, IGFBP2, KL и SIRT1 связываются с 7, 19, 11, 13 и 6 miRNA со свободной энергией взаимодействия равной -134 кДж/моль, -142 кДж/моль, -140 кДж/моль, -142 кДж/моль и -138 кДж/моль, соответственно. В mRNA нескольких генов выявлены кластеры сайтов связывания miRNA с наложением нуклеотидных последовательностей. Несколько ассоциаций miRNA и генов предлагаются в качестве биомаркеров для разработки методов диагностики метаболического синдрома.
Ключевые слова: miRNA, mRNA, метаболический синдром, гены кандидаты.
Библиографические ссылки
1 Lupton SJ., Chiu CL., Lind JM. A hypertension gene: are we there yet? // Twin Res Hum Genet. -2011. - Vol. 14, No.4. – P.295-304. doi: 10.1375/twin.14.4.295.
2 Stančáková A., Laakso M. Genetics of metabolic syndrome // Rev Endocr Metab Disord. – 2014. - Vol. 15, No.4. – P.243-252. doi: 10.1007/s11154-014-9293-9.
3 Aleksandrova K., Boeing H., Jenab M., et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study // Cancer Prev. Res. - 2011. - Vol. 4. - P. 1873–1883.
4 Ambler SK., Brown RD. Genetic determinants of blood pressure regulation // J Cardiovasc Nurs. – 1999. - Vol. 13, No.4. – P.59-77.
5 Bochud M., Bovet P., Burnier M., Eap CB. CYP3A5 and ABCB1 genes and hypertension //. Pharmacogenomics. – 2009. - Vol. 10, No.3. – P.477-487. doi: 10.2217/14622416.10.3.477.
6 Gatti RR., Santos PS., Sena AA., Marangoni K., Araújo MA., Goulart LR. The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension // J Renin Angiotensin Aldosterone Syst. – 2013. - Vol. 14, No.4. – P.360-368. doi: 10.1177/1470320312452027.
7 Chen K., Fu C., Chen C., et al Role of GRK4 in the regulation of arterial AT1 receptor in hypertension // Hypertension. – 2014. - Vol. 63, No.2. – P.289-296. doi: 10.1161/HYPERTENSIONAHA.113.01766.
8 Vargas T., Moreno-Rubio J., Herranz J. Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer // Mol Oncol. – 2014. - Vol. 8, No.8. – P.1469-1481. doi: 10.1016/j.molonc.2014.05.015.
9 Hagiwara S., Kantharidis P., Cooper ME. MicroRNA as biomarkers and regulator of cardiovascular development and disease // Curr Pharm Des. – 2014. - Vol. 20, No.14. – P.2347-2370.
10 Yuan LQ., de Jesus Perez V., Liao XB., Król M., Yeh CH. MicroRNA and Cardiovascular Disease 2016 // Biomed Res Int. – 2017. - Vol. 2017. – P.3780513. doi: 10.1155/2015/734380.
11 Bátkai S., Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets // Curr Hypertens Rep. – 2012. - Vol. 14, No.1. – P.79-87. doi: 10.1007/s11906-011-0235-6. 12 Zhongguo Zhong Yao Za Zhi. MicroRNA and hypertension // Article in Chinese. – 2014. - Vol. 39, No.3. – P.397-401;
13 Meloche J., Paulin R., Provencher S., Bonnet S. Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension // Curr Vasc Pharmacol. – 2015. - Vol. 13, No.3. – P.331-340.
14 Zhou G., Chen T., Raj JU. MicroRNAs in pulmonary arterial hypertension // Am J Respir Cell Mol Biol. – 2015. - Vol. - 52, No.2. – P.139-151. doi: 10.1165/rcmb.2014-0166TR.
15 Synetos A., Toutouzas K., Stathogiannis K., Latsios G., Tsiamis E., Tousoulis D., Stefanadis C. MicroRNAs in arterial hypertension // Curr Top Med Chem. – 2013. - Vol. 13, No.13. – P.1527-1532.
16 Boucherat O., Potus F., Bonnet S. microRNA and Pulmonary Hypertension // Adv Exp Med Biol. – 2015. - Vol. 888. – P.237-252. doi: 10.1007/978-3-319-22671-2_12.
17 Bienertova-Vasku J., Novak J., Vasku A. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment // J Am Soc Hypertens. – 2015. - Vol. 9, No.3. - P.221-234. doi: 10.1016/j.jash.2014.12.011.
18 Lee A., McLean D., Choi J., Kang H., Chang W., Kim J. Therapeutic implications of microRNAs in pulmonary arterial hypertension // BMB Rep. – 2014. - Vol. 47, No.6. - P.311-317.
19 Karolina DS., Tavintharan S., Armugam A., et al Circulating miRNA profiles in patients with metabolic syndrome // J Clin Endocrinol Metab. – 2012. - Vol. 97, No.12 - P.2271-2276. doi: 10.1210/jc.2012-1996.
20 Price NL., Ramírez CM., Fernández-Hernando C. Relevance of microRNA in metabolic diseases // Crit Rev Clin Lab Sci. – 2014. - Vol. 51, No.6. - P.305-320. doi: 10.3109/10408363.2014.937522.
21 Ramírez CM., Goedeke L., Fernández-Hernando C. "Micromanaging" metabolic syndrome // Cell Cycle. – 2011. - Vol. 10, No.19. - P.3249-3252. doi: 10.4161/cc.10.19.17558.
22 Londin E., Lohera P., Telonisa A.G., Quanna K. et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate and tissue-specific microRNAs // PNAS USA. – 2015. – Vol.112. – P.1106-1115. doi: 10.1073/pnas.1420955112.
23 Ivashchenko A.T., Pyrkova A.Y., Niyazova R.Y., Alybayeva A., Baskakov K. Prediction of miRNA binding sites in mRNA // Bioinformation. – 2016. - Vol.12. – P.237-240.
24 Kool E.T. Hydrogen bonding, base stacking, and steric effects in DNA replication // Annual Review of Biophysics and Biomolecular Structure. – 2001. - Vol.30. P.1–22. doi:10.1146/annurev.biophys.30.1.1.
25 Leontis N.B., Stombaugh J., Westhof E. The non-Watson- Crick base pairs and their associated isostericity matrices // Nucleic Acids Research. – 2002. - Vol.30. P.3497–3531.
References
1. Aleksandrova K., Boeing H., Jenab M., et al. (2011) Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev. Res., vol. 4, р. 1873–1883.
2. Ambler SK., Brown RD. (1999) Genetic determinants of blood pressure regulation. J Cardiovasc Nurs., vol. 13(4), р.59-77.
3. Bátkai S., Thum T. (2012) MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep., vol. 14(1), р.79-87. doi: 10.1007/s11906-011-0235-6.
4. Bienertova-Vasku J., Novak J., Vasku A. (2015) MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens., vol. 9(3), р.221-234. doi: 10.1016/j.jash.2014.12.011.
5. Bochud M., Bovet P., Burnier M., Eap CB. CYP3A5 and ABCB1 genes and hypertension (2009) Pharmacogenomics, vol. 10(3), р.477-487. doi: 10.2217/14622416.10.3.477.
6. Boucherat O., Potus F., Bonnet S. (2015) microRNA and Pulmonary Hypertension. Adv Exp Med Biol., vol. 888, р.237-252. doi: 10.1007/978-3-319-22671-2_12.
7. Chen K., Fu C., Chen C., et al. (2014) Role of GRK4 in the regulation of arterial AT1 receptor in hypertension Hypertension, vol. 63(2), р.289-296. doi: 10.1161/HYPERTENSIONAHA.113.01766.
8. Gatti RR., Santos PS., Sena AA., Marangoni K., Araújo MA., Goulart LR. (2013) The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension. J Renin Angiotensin Aldosterone Syst., vol. 14(4), р.360-368. doi: 10.1177/1470320312452027.
9. Hagiwara S., Kantharidis P., Cooper ME. (2014) MicroRNA as biomarkers and regulator of cardiovascular development and disease. Curr Pharm Des., vol. 20(14), р.2347-2370.
10. Ivashchenko A.T., Pyrkova A.Y., Niyazova R.Y., Alybayeva A., Baskakov K. (2016) Prediction of miRNA binding sites in mRNA. Bioinformation., vol.12, p.237-240.
11. Karolina DS., Tavintharan S., Armugam A., et al (2012) Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab., vol. 97(12), р.2271-2276. doi: 10.1210/jc.2012-1996.
12. Kool E.T. (2001) Hydrogen bonding, base stacking, and steric effects in DNA replication. Annual Review of Biophysics and Biomolecular Structure., vol.30, p.1–22. doi:10.1146/annurev.biophys.30.1.1.
13. Lee A., McLean D., Choi J., Kang H., Chang W., Kim J. (2014) Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep., vol. 47(6), p.311-317.
14. Leontis N.B., Stombaugh J., Westhof E. (2002) The non-Watson-Crick base pairs and their associated isostericity matrices. Nucleic Acids Research., vol.30, p.3497–3531.
15. Londin E., Lohera P., Telonisa A.G., Quanna K. et al. (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate and tissue-specific microRNAs. PNAS USA., vol.112, p.1106-1115. doi: 10.1073/pnas.1420955112. 16. Lupton SJ., Chiu CL., Lind JM. (2011) A hypertension gene: are we there yet? Twin Res Hum Genet., vol. 14(4), p.295-304. doi: 10.1375/twin.14.4.295.
17. Meloche J., Paulin R., Provencher S., Bonnet S. (2015) Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension. Curr Vasc Pharmacol., vol. 13(3), p.331-340.
18. Price NL., Ramírez CM., Fernández-Hernando C. (2014) Relevance of microRNA in metabolic diseases. Crit Rev Clin Lab Sci., vol. 51(6), p.305-320. doi: 10.3109/10408363.2014.937522.
19. Ramírez CM., Goedeke L., Fernández-Hernando C. (2011) "Micromanaging" metabolic syndrome. Cell Cycle., vol. 10(19), p.3249-3252. doi: 10.4161/cc.10.19.17558.
20. Stančáková A., Laakso M. (2014) Genetics of metabolic syndrome. Rev Endocr Metab Disord., vol. 15(4), p.243-252. doi: 10.1007/s11154-014-9293-9.
21. Synetos A., Toutouzas K., Stathogiannis K., Latsios G., Tsiamis E., Tousoulis D., Stefanadis C. (2013) MicroRNAs in arterial hypertension. Curr Top Med Chem. vol. 13(13), p.1527-1532.
22. Vargas T., Moreno-Rubio J., Herranz J. (2014) Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer. Mol Oncol., vol. 8(8), p.1469-1481. doi: 10.1016/j.molonc.2014.05.015.
23. Yuan LQ., de Jesus Perez V., Liao XB., Król M., Yeh CH. (2017) MicroRNA and Cardiovascular Disease 2016. Biomed Res Int., vol. 2017, p.3780513. doi: 10.1155/2015/734380. 24. Zhongguo Zhong Yao Za Zhi. (2014) MicroRNA and hypertension. Article in Chinese, vol. 39(3), p.397-401;
25. Zhou G., Chen T., Raj JU. (2015) MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. vol. - 52(2), p.139-151. doi: 10.1165/rcmb.2014-0166TR
2 Stančáková A., Laakso M. Genetics of metabolic syndrome // Rev Endocr Metab Disord. – 2014. - Vol. 15, No.4. – P.243-252. doi: 10.1007/s11154-014-9293-9.
3 Aleksandrova K., Boeing H., Jenab M., et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study // Cancer Prev. Res. - 2011. - Vol. 4. - P. 1873–1883.
4 Ambler SK., Brown RD. Genetic determinants of blood pressure regulation // J Cardiovasc Nurs. – 1999. - Vol. 13, No.4. – P.59-77.
5 Bochud M., Bovet P., Burnier M., Eap CB. CYP3A5 and ABCB1 genes and hypertension //. Pharmacogenomics. – 2009. - Vol. 10, No.3. – P.477-487. doi: 10.2217/14622416.10.3.477.
6 Gatti RR., Santos PS., Sena AA., Marangoni K., Araújo MA., Goulart LR. The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension // J Renin Angiotensin Aldosterone Syst. – 2013. - Vol. 14, No.4. – P.360-368. doi: 10.1177/1470320312452027.
7 Chen K., Fu C., Chen C., et al Role of GRK4 in the regulation of arterial AT1 receptor in hypertension // Hypertension. – 2014. - Vol. 63, No.2. – P.289-296. doi: 10.1161/HYPERTENSIONAHA.113.01766.
8 Vargas T., Moreno-Rubio J., Herranz J. Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer // Mol Oncol. – 2014. - Vol. 8, No.8. – P.1469-1481. doi: 10.1016/j.molonc.2014.05.015.
9 Hagiwara S., Kantharidis P., Cooper ME. MicroRNA as biomarkers and regulator of cardiovascular development and disease // Curr Pharm Des. – 2014. - Vol. 20, No.14. – P.2347-2370.
10 Yuan LQ., de Jesus Perez V., Liao XB., Król M., Yeh CH. MicroRNA and Cardiovascular Disease 2016 // Biomed Res Int. – 2017. - Vol. 2017. – P.3780513. doi: 10.1155/2015/734380.
11 Bátkai S., Thum T. MicroRNAs in hypertension: mechanisms and therapeutic targets // Curr Hypertens Rep. – 2012. - Vol. 14, No.1. – P.79-87. doi: 10.1007/s11906-011-0235-6. 12 Zhongguo Zhong Yao Za Zhi. MicroRNA and hypertension // Article in Chinese. – 2014. - Vol. 39, No.3. – P.397-401;
13 Meloche J., Paulin R., Provencher S., Bonnet S. Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension // Curr Vasc Pharmacol. – 2015. - Vol. 13, No.3. – P.331-340.
14 Zhou G., Chen T., Raj JU. MicroRNAs in pulmonary arterial hypertension // Am J Respir Cell Mol Biol. – 2015. - Vol. - 52, No.2. – P.139-151. doi: 10.1165/rcmb.2014-0166TR.
15 Synetos A., Toutouzas K., Stathogiannis K., Latsios G., Tsiamis E., Tousoulis D., Stefanadis C. MicroRNAs in arterial hypertension // Curr Top Med Chem. – 2013. - Vol. 13, No.13. – P.1527-1532.
16 Boucherat O., Potus F., Bonnet S. microRNA and Pulmonary Hypertension // Adv Exp Med Biol. – 2015. - Vol. 888. – P.237-252. doi: 10.1007/978-3-319-22671-2_12.
17 Bienertova-Vasku J., Novak J., Vasku A. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment // J Am Soc Hypertens. – 2015. - Vol. 9, No.3. - P.221-234. doi: 10.1016/j.jash.2014.12.011.
18 Lee A., McLean D., Choi J., Kang H., Chang W., Kim J. Therapeutic implications of microRNAs in pulmonary arterial hypertension // BMB Rep. – 2014. - Vol. 47, No.6. - P.311-317.
19 Karolina DS., Tavintharan S., Armugam A., et al Circulating miRNA profiles in patients with metabolic syndrome // J Clin Endocrinol Metab. – 2012. - Vol. 97, No.12 - P.2271-2276. doi: 10.1210/jc.2012-1996.
20 Price NL., Ramírez CM., Fernández-Hernando C. Relevance of microRNA in metabolic diseases // Crit Rev Clin Lab Sci. – 2014. - Vol. 51, No.6. - P.305-320. doi: 10.3109/10408363.2014.937522.
21 Ramírez CM., Goedeke L., Fernández-Hernando C. "Micromanaging" metabolic syndrome // Cell Cycle. – 2011. - Vol. 10, No.19. - P.3249-3252. doi: 10.4161/cc.10.19.17558.
22 Londin E., Lohera P., Telonisa A.G., Quanna K. et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate and tissue-specific microRNAs // PNAS USA. – 2015. – Vol.112. – P.1106-1115. doi: 10.1073/pnas.1420955112.
23 Ivashchenko A.T., Pyrkova A.Y., Niyazova R.Y., Alybayeva A., Baskakov K. Prediction of miRNA binding sites in mRNA // Bioinformation. – 2016. - Vol.12. – P.237-240.
24 Kool E.T. Hydrogen bonding, base stacking, and steric effects in DNA replication // Annual Review of Biophysics and Biomolecular Structure. – 2001. - Vol.30. P.1–22. doi:10.1146/annurev.biophys.30.1.1.
25 Leontis N.B., Stombaugh J., Westhof E. The non-Watson- Crick base pairs and their associated isostericity matrices // Nucleic Acids Research. – 2002. - Vol.30. P.3497–3531.
References
1. Aleksandrova K., Boeing H., Jenab M., et al. (2011) Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev. Res., vol. 4, р. 1873–1883.
2. Ambler SK., Brown RD. (1999) Genetic determinants of blood pressure regulation. J Cardiovasc Nurs., vol. 13(4), р.59-77.
3. Bátkai S., Thum T. (2012) MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep., vol. 14(1), р.79-87. doi: 10.1007/s11906-011-0235-6.
4. Bienertova-Vasku J., Novak J., Vasku A. (2015) MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens., vol. 9(3), р.221-234. doi: 10.1016/j.jash.2014.12.011.
5. Bochud M., Bovet P., Burnier M., Eap CB. CYP3A5 and ABCB1 genes and hypertension (2009) Pharmacogenomics, vol. 10(3), р.477-487. doi: 10.2217/14622416.10.3.477.
6. Boucherat O., Potus F., Bonnet S. (2015) microRNA and Pulmonary Hypertension. Adv Exp Med Biol., vol. 888, р.237-252. doi: 10.1007/978-3-319-22671-2_12.
7. Chen K., Fu C., Chen C., et al. (2014) Role of GRK4 in the regulation of arterial AT1 receptor in hypertension Hypertension, vol. 63(2), р.289-296. doi: 10.1161/HYPERTENSIONAHA.113.01766.
8. Gatti RR., Santos PS., Sena AA., Marangoni K., Araújo MA., Goulart LR. (2013) The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension. J Renin Angiotensin Aldosterone Syst., vol. 14(4), р.360-368. doi: 10.1177/1470320312452027.
9. Hagiwara S., Kantharidis P., Cooper ME. (2014) MicroRNA as biomarkers and regulator of cardiovascular development and disease. Curr Pharm Des., vol. 20(14), р.2347-2370.
10. Ivashchenko A.T., Pyrkova A.Y., Niyazova R.Y., Alybayeva A., Baskakov K. (2016) Prediction of miRNA binding sites in mRNA. Bioinformation., vol.12, p.237-240.
11. Karolina DS., Tavintharan S., Armugam A., et al (2012) Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab., vol. 97(12), р.2271-2276. doi: 10.1210/jc.2012-1996.
12. Kool E.T. (2001) Hydrogen bonding, base stacking, and steric effects in DNA replication. Annual Review of Biophysics and Biomolecular Structure., vol.30, p.1–22. doi:10.1146/annurev.biophys.30.1.1.
13. Lee A., McLean D., Choi J., Kang H., Chang W., Kim J. (2014) Therapeutic implications of microRNAs in pulmonary arterial hypertension. BMB Rep., vol. 47(6), p.311-317.
14. Leontis N.B., Stombaugh J., Westhof E. (2002) The non-Watson-Crick base pairs and their associated isostericity matrices. Nucleic Acids Research., vol.30, p.3497–3531.
15. Londin E., Lohera P., Telonisa A.G., Quanna K. et al. (2015) Analysis of 13 cell types reveals evidence for the expression of numerous novel primate and tissue-specific microRNAs. PNAS USA., vol.112, p.1106-1115. doi: 10.1073/pnas.1420955112. 16. Lupton SJ., Chiu CL., Lind JM. (2011) A hypertension gene: are we there yet? Twin Res Hum Genet., vol. 14(4), p.295-304. doi: 10.1375/twin.14.4.295.
17. Meloche J., Paulin R., Provencher S., Bonnet S. (2015) Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension. Curr Vasc Pharmacol., vol. 13(3), p.331-340.
18. Price NL., Ramírez CM., Fernández-Hernando C. (2014) Relevance of microRNA in metabolic diseases. Crit Rev Clin Lab Sci., vol. 51(6), p.305-320. doi: 10.3109/10408363.2014.937522.
19. Ramírez CM., Goedeke L., Fernández-Hernando C. (2011) "Micromanaging" metabolic syndrome. Cell Cycle., vol. 10(19), p.3249-3252. doi: 10.4161/cc.10.19.17558.
20. Stančáková A., Laakso M. (2014) Genetics of metabolic syndrome. Rev Endocr Metab Disord., vol. 15(4), p.243-252. doi: 10.1007/s11154-014-9293-9.
21. Synetos A., Toutouzas K., Stathogiannis K., Latsios G., Tsiamis E., Tousoulis D., Stefanadis C. (2013) MicroRNAs in arterial hypertension. Curr Top Med Chem. vol. 13(13), p.1527-1532.
22. Vargas T., Moreno-Rubio J., Herranz J. (2014) Genes associated with metabolic syndrome predict disease-free survival in stage II colorectal cancer patients. A novel link between metabolic dysregulation and colorectal cancer. Mol Oncol., vol. 8(8), p.1469-1481. doi: 10.1016/j.molonc.2014.05.015.
23. Yuan LQ., de Jesus Perez V., Liao XB., Król M., Yeh CH. (2017) MicroRNA and Cardiovascular Disease 2016. Biomed Res Int., vol. 2017, p.3780513. doi: 10.1155/2015/734380. 24. Zhongguo Zhong Yao Za Zhi. (2014) MicroRNA and hypertension. Article in Chinese, vol. 39(3), p.397-401;
25. Zhou G., Chen T., Raj JU. (2015) MicroRNAs in pulmonary arterial hypertension. Am J Respir Cell Mol Biol. vol. - 52(2), p.139-151. doi: 10.1165/rcmb.2014-0166TR
Загрузки
Как цитировать
Atambayeva S. А., Niyazova R. Е., Ivashchenko A. Т., Yurikova, O. Y., & Mukushkina, D. D. (2019). характеристики взаимодействия miRNA c 5’UTR, CDS и 3’UTR mRNA кандидатных генов метаболического синдром. Вестник КазНУ. Серия биологическая, 78(1), 100–113. https://doi.org/10.26577/eb-2019-1-1385
Выпуск
Раздел
МОЛЕКУЛЯРНАЯ БИОЛОГИЯ И ГЕНЕТИКА
